News Manufacturing issues scupper Savara's lead drug filing Savara shares are pummelled after the FDA says it cannot accept a filing for lead drug Molbreevi, but it is still hopeful of an approval in 2026.
News Sanofi pledges a $20 billion investment programme in the US Sanofi is the latest European pharma group to promise a big capital investment programme on manufacturing and R&D in the US.
R&D For cell therapies, raw material quality hinges on the human... When it comes to cell-based therapy manufacturing, the concept of quality management carries important distinctions from more traditional therapeutics production.
News Gilead ups its US investment plans by $11 billion Gilead Sciences has joined the list of pharma groups hiking their capital investment plans in the US.
News FDA ramps up unannounced inspections of foreign facilities Trump orders the FDA to ease the commissioning of domestic manufacturing facilities, as the regulator announces more unannounced foreign inspections.
News GSK "well positioned" to weather pharma tariffs GSK has said it is not too worried about the impact of potential pharma-specific US tariff rules as it posts a solid set of first-quarter results.
News Bayer trial combines two top drugs for kidney disease Data from the CONFIDENCE trial shows the value of combining Bayer's Kerendia with an SGLT2 inhibitor to treat chronic kidney disease in diabetics.